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FINANCIAL BARRIERS TO ORGAN TRANSPLANTATION: A COMPARATIVE
ANALYSIS
ASHLEY C. RENKES
Grand Valley State University

ABSTRACT
Organ procurement and transplantation is an expensive process. Because of economic concerns,
hospitals often refuse to list otherwise qualified patients for transplant unless that patient has the
financial means to pay for the transplant and related services. This prevents patients from
receiving lifesaving organ transplants even when they are medically qualified. Since the
financial aspect of transplant is a concern in the United States, this paper explores the origin of
the barriers, and through the literature compares barriers to those in other countries performing
organ transplants. It also explores ways for patients to overcome financial barriers to
transplantation.
Keywords: organ transplant, financial barriers, international comparison

INTRODUCTION
Capitalism reserves goods for those that can afford to buy them. In the case of organ donation
in the United States, it is illegal to buy or sell organs; however, a significant economy exists
surrounding the business of procuring and transplanting organs. The transplant recipient incurs
all charges related to organ procurement and transplantation. This creates an enormous burden
for the patient or his insurance provider. Obtaining funding for an organ transplant can be the
difference between life and death for patients who don’t have adequate health insurance, or lack
health insurance.
Major religions, organ procurement organizations (OPO), and transplant centers consider organ
donation a benevolent act. Despite this, the price tag affixed to each lifesaving organ is far from
benevolent. While we (as a society) shift the cost of procurement and transplantation away from
the donor and her family, we don’t always consider the burden for the transplant recipient.
Defining financial barriers to solid organ transplant as: A condition related to paying for an
organ transplant that if not met, precludes the patient from receiving a solid organ transplant; it is
important to understand the charges associated with organ transplant and their origins in order to
grasp the burden placed on patients who need lifesaving transplants. It is also necessary to
understand the financial burden in order to explore alternatives for funding procedures and
medications associated with transplantation, noting that payment for organ transplants is a
subjective arrangement defined by the specific transplant center treating the patient, and
necessary conditions may vary from center to center.
Most importantly, we can learn from and compare the American transplant system to other
developed countries with modern healthcare systems. There is a principal question in this paper:
What financial barriers to solid organ transplantation exist; and comparatively, do Americans
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face more financial barriers to transplantation than patients in other developed nations with
modern healthcare systems? These issues are explored considering the current limitations of
living and deceased organ donor availability, and the realities of profit in the American
healthcare system.

ORGAN PROCUREMENT AND TRANSPLANT OVERVIEW
Procurement and Transplantation
Procurement and transplantation are two unique processes in the American donation and
transplantation system. Organ procurement encompasses donor evaluation, obtaining consent for
donation, medically managing the donor, and placing the organs with transplant centers
according to United Network for Organ Sharing (UNOS) policy. Currently, UNOS indicates over
111,000 patients are waiting for an organ transplant (a number which increases by thousands of
patients every year), while numbers of organs donors remain relatively static over time (OPTN
2009).
Organ procurement is managed by one of 58 federally designated OPOs who are either
independent nonprofit organizations or nonprofits associated with a major university (e.g. the
University of Wisconsin). Transplantation occurs after a transplant center (a hospital that
performs organ transplants) accepts an organ from a donor managed by an OPO. Typically, the
transplant center’s surgeons surgically recover an organ for their patient. Alternatively, the OPO
can arrange for a compensated, qualified, third-party surgeon to recover the organ. The organ is
then transported back to the transplant center and the transplant surgery is performed on the
recipient. All of the costs related to donor’s medical management, the procurement of a specific
organ, and the transplant surgery are billed to the recipient via the transplant center. The
distribution of charges is a complex process managed by the OPO in collaboration with the
transplant center and donor hospital.
Aftercare and Medication
Aside from charges associated with organ procurement and transplantation procedures, there is
a significant cost associated with the recipient’s aftercare and anti-rejection medication. This
adds an onerous annual expense to the existing financial burden associated with the transplant
surgery. Many transplant centers include the cost of anti-rejection medication in their assessment
of a patient’s ability to pay for a transplant. This additional consideration increases the
likelihood that a patient won’t have the appropriate funds for their transplant, and won’t be listed
at a transplant center because of their financial status. Transplant centers often require proof of
assets or adequate health insurance to consider listing a patient with UNOS. The rationale behind
this practice is to ensure that the patient will have appropriate aftercare, and be able to afford
their anti-rejection medication. It also ensures that the transplant center is reimbursed for its
expenditures related to the donation.
Although this process may seem fair and equitable for reimbursing involved parties, it often
presents such an enormous burden for the patient and her family that she is unable to survive the
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process of finding insurance or other funds, and becomes one of 16-17 people who die each day
waiting for an organ transplant (OPTN 2009).
Expenditures Associated with Transplantation and Related Processes
In 2008 the Milliman firm developed an actuarial report that outlined the total cost of solid
organ transplant. In the report, Milliman uses data provided by the Organ Procurement and
Transplant Network (OPTN), whose programs are currently managed by UNOS. Milliman
(2008) averaged costs associated with all transplantations performed on American citizens the
year prior, and estimates the cost of procurement according to 2005 and 2006 data from Texas
and Washington based OPOs. The firm included the following data: thirty days of pre-transplant
hospitalization and associated charges; procurement services; hospital charges associated with
the transplant; physician’s fees; 180 days post-transplant hospital admission (initial
hospitalization and repeat hospitalization after initial discharge, and outpatient procedures and
laboratory services); and the cost of medication (anti-rejection, etc.) associated with pre and
post-transplant prescriptions within 180 days (Milliman 2008). This thorough analysis of the
overall cost of obtaining an organ transplant is the basis for further analysis.
The intestine is the most expensive single organ transplant, averaging $1,121,800 per transplant
(Milliman 2008). The kidney is the least expensive at only $259,900. Other transplants range
from $275,500 to $787,700 per organ (Milliman 2008). Multiple organ transplants escalate these
costs to well over the million-dollar mark, with the exception of liver-kidney and kidneypancreas transplants. Lung transplants are considered single organ transplants whether or not
both lungs are transplanted into the same recipient, and Milliman provides estimates for both
single and double lung transplants. It is important to note that Milliman assumed in their
calculations that these charges are associated with patients with full-coverage insurance
(Milliman 2008). The total cost for a private-pay patient could be much higher without the
benefit of an insurance company’s negotiated rate agreements. In Chisholm (2007), a 2001
survey conducted by the author indicated that the first year of post-transplant medication
exceeded $20,000. In Chisholm (2005), the estimate stood at $12,000 per year in the years
following the initial post-transplant year. This data is also reflected in the Milliman (2008) study.
There is an argument within the transplant community that only those who have the ability to
take care of their organ post-transplant should be listed at a transplant center. Because of this
consideration, and the economic needs of the hospital, finances appear among the various and
extensive criteria used to assess the health status of a potential transplant patient. With a noted
increase in patients waiting for a transplant, and relatively stable donation rates, it is apparent
transplant centers have some place to be “picky” about their patients (Pomfret et al. 2007). For
example, the state of Michigan has approximately 3,000 patients waiting for an organ per month,
and approximately 300 donors per year donating approximately 950 organs (OPTN 2009). With
no shortage of transplant business and a large shortage of organs, some could argue that only the
“best” candidates should receive organ transplants.
If the transplant center wants to improve its cost structure, it will probably have to
transplant only better candidates with better organs so that the patients will have short
lengths of stays and use fewer resources. But transplant volume may decrease (Howard
2007).
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On the other hand, considering the financial assets or insurance of a patient in the listing process
could prevent patients who are very medically suitable for donation (“better candidates”) from
receiving their life saving transplants.
The importance of finance in transplant is apparent in the materials provided to transplant
patients by Tulane Medical Center in New Orleans, Louisiana:
The staff at the Tulane Abdominal Transplant Institute (TATI) understand the importance
of considering the financial aspects of organ transplantation. Because of this, we have
included financial issues in our patient care services…[Transplant Financial Counselors]
collaborate and communicate with the Insurance Companies, Medicare and Medicaid
offices, and with the clinical and social services of the transplant team to provide a
complete financial plan of care for each individual patient . Most patients cannot afford a
transplant without some type of health insurance coverage (Tulane 2009).
This is strong language defining the importance of money in the process of being listed at a
transplant center and subsequently receiving a transplant. While transplant centers are often
willing to work with patients to secure funding, some patients don’t survive the lengthy process.
Hospital administrators want both high volume and outstanding results. But they also want
the program to have an ‘excess of revenues over expenses’ (not-for-profit hospitals do not
have ‘profits’) (Howard 2007).
If a patient doesn’t have the financial resources to pay for a transplant and associated care and
medications, transplant centers will not place a patient on the waiting list despite the ability to
save his life with a transplant.

COMPARATIVE FINANCIAL ANALYSIS AND BARRIERS OUTSIDE THE U.S.
Hospitals in the United States are not unique in their ability to perform organ transplants. Many
other countries perform organ transplants successfully. Comparatively, do other countries’
citizens face the same financial considerations when confronted with organ transplantation?
Italy
Comparatively, Italy’s transplant rates are much lower than the United States; Italy transplants
19 per million population while the United States transplants 24 per million (Miceli 2000).
Miceli (2000) studied a patient’s level of education as a socio-economic indicator related to
organ donation. The results of the study showed that despite free healthcare and organ
transplantation in Italy (on all accounts, an absence of economic barriers), the absence did not
reduce the level of discrimination in access to transplant (Miceli 2000). It is interesting to note
when considering the burden of cost related to American transplants that there were still other
barriers associated with transplant in Italy, preventing people from being transplanted when
appropriate. Other barriers included community support of organ donation, with the level of
community education as a strong indicator for or against organ donation support.
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Japan
The Japanese enjoy relatively healthy lives and the third longest average lifespan in the world
at 82.12 years (CIA World Factbook 2009). Healthcare is accessible, and insurance is affordable
(Fukuhara 2007). The Japanese do not pay significant out-of-pocket healthcare expenses, and
insurance co-pays are capped per month. Despite this relative affordability, Japanese citizens
also have barriers to organ transplantation:
Experts from various fields have hypothesized why organ transplant rates are so low in
Japan and why so few are from donation after brain death (DBD) donors. Several of their
theories stem from spiritual beliefs…Others, including members of congress and some
physician groups, believe that a DBD donor still contains a spirit. Under this belief system,
removing organs from a DBD donor is equivalent to murder...even today, physicians who
perform organ transplantation are sometimes sued for their actions (Fukuhara 2007).
Further confounding the lack of organ donations and transplants in Japan is the nation’s cultural
opposition to brain dead organ donation. From 1968 to 1999 there were no brain dead organ
donors in Japan (Sato 1999). In 1992 the Japanese government determined that brain death was
in fact death, but cultural taboos surrounding the condition of a dead patient with a heartbeat
continued to create a non-financial barrier to donation (Sato 1999). Nearly 300 Japanese citizens
sought solid organ transplants outside of Japan in those years (Sato 1999). Donation after cardiac
death (patients declared death by cardio-respiratory means) supplied kidneys to Japanese donors
during this time. Japan’s transplants per million have not been adequately reported in the
literature, and donation remains a relatively taboo subject.
Japanese citizens still face a shortage of transplant services even without financial barriers.
Unfortunately, without major cultural change in Japan, whole organ transplant will remain an
unusual occurrence (Fukuhara 2007).
The United Kingdom
The United Kingdom lags behind the United States, Spain, and Italy with only 13 transplants
per million (Rudge 2006). The United Kingdom publicly funds healthcare for all residents with
tax dollars. Some residents choose to supplement their government funded healthcare with
private insurance in order to circumvent wait times and public facilities. Patients in need of an
organ transplant are not faced with financial barriers. Transplant patients in the United Kingdom
face issues related to a low supply of transplantable organs (Rudge 2006). A lack of physician
consensus on the appropriate time to declare brain death results in fewer patients being
considered for organ donation overall, despite the ability for a patient to become a donor after
cardiac death (Rudge 2006). Patients that donate after cardiac death are typically only able to
donate livers and kidneys, creating a shortage of other organs if brain dead donors are not
available. Of all brain dead patients eligible to donate their organs, organ donation officials only
approach 85 percent of patients’ families about donation (Rudge 2006). Out of the 85 percent of
all organ donor families approached for donation, 41 percent declined donation (Rudge 2006).
Again, despite a lack of financial barriers, patients in the UK face organ shortages that result in
fewer transplanted organs per million than in the United States.
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Spain
Spain excels in the area of organ donation. Spain’s presumed consent system results in
significantly higher consent rates for donation than other developed countries; as a result, Spain
has 33 transplants per million population (Matesanz 2009). The Spanish single-payer healthcare
system provides free care to all residents:
The most common complaint of patients is the long wait to see specialists and undergo
certain procedures. On the other hand, a study published last year in the U.S. journal Health
Affairs found that in Spain, there are a third fewer deaths caused by delayed access to health
care than in the United States. Spain's constitution, drawn up in 1978 following the Franco
dictatorship, not only guarantees the right to universal health care, it also requires the state
to provide it. The World Health Organization's ranking system puts Spain's health care
system seventh in the world, well ahead of America, even though it spends much less on
health care (Socolovsky 2009).
Like the United Kingdom, Spanish residents also have the option of supplementing their free
healthcare with private pay insurance (Socolovsky 2009). Access to private pay insurance may
expedite a patient’s initial assessment for transplantation, but Spanish residents, like those in the
United Kingdom, cannot be turned away from a transplant waiting list because of their inability
to pay. Spanish patients do cover the burden of some of their medication costs; however, this is
not considered a significant cost within the Spanish transplant system, known as the world’s best
(Socolovsky 2009).
DISCUSSION
These comparisons offer perspective on the financial barriers effecting patients in the United
States; however, any barriers to transplant result in additional preventable deaths. It is important
to overcome barriers of any origin to maximize a patient’s chances of receiving a lifesaving
organ. The comparisons between the American transplant system and other developed countries
are limited by the profit-driven nature of the American medical culture. Developed healthcare
systems in the United Kingdom, Japan, Spain, and Italy offer either low-cost health insurance or
are engaged in single-payer government-funded systems. Despite these differences, it is apparent
that while the primary barrier to transplantation in the United States (other than a shortage of
organs) is financial in nature; other developed countries face non-financial barriers that restrict
their relative rates of organ donation and transplantation. Excluding Spain, the United States is
still able to transplant more organs per million population than any other healthcare system in
this comparison. The keen difference lies in the ethical nature of financial barriers and a patient’s
ability or inability to pay as the line between life and death. In single-payer government funded
healthcare systems and systems with easily accessible affordable healthcare insurance, every
patient has roughly the same access to healthcare services where they would receive services
based on organ availability.
In Jacobson and Mathur (2010), the competing values of profit and mission in healthcare are
explored in the context of improving healthcare delivery through health law. Economic realities
of the market force hospitals to compete for patients and resources (Jacobson and Mathur 2010).
The American hospital’s need to remain financially viable in order to serve a patient population
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is especially relevant to the conundrum of financial barriers in organ transplantation. Without
radical public policy reforms that move the United States into a single-payer government
healthcare system, or into a system that offers widespread affordable healthcare insurance plans,
Americans have to work with the existing systems of organ procurement and transplantation. It
stands that without profit, or some source of revenue to sustain operations, a transplant center
would cease to exist, removing an important healthcare resource from the community (Jacobson
and Mathur 2010). Although the other countries in this analysis may have more consistent access
to transplant services because of the nature of their payment systems, their other barriers to
transplantation result in systems where fewer organs are transplanted per capita than in the
United States; Spain being the exception, enjoying the fruit of a presumed-consent culture of
donation. Ideally, a system that combined the donation culture of the United States and Spain
(increasing available organs for transplant) and the payment systems of Spain and its
counterparts (roughly leveling the financial playing field) would provide the best possible
conditions for receiving an organ transplant in our current age of medical technology.
APPROACHES TO OVERCOMING FINANCIAL BARRIERS
Barriers to being listed for a possible organ transplant emerge as patients face financial
obstacles. Finances related to the actual procedures and medications have been discussed at
length; however, there are a number of ways patients can supplement their own assets or
insurance in order to qualify for transplantation. In Chisholm (2007), the author explores a
problem associated with the high cost of transplant: “One of the leading causes of nonadherence
among renal transplant recipients is the high cost of posttransplant medications, including
immunosuppressant agents and medications to treat comorbid conditions” (Chisholm 2007).
“Medication Assistance Programs” for transplant recipients (like the Michigan-based grants
funded by the Gift of Life Foundation) result in better organ function over time, and increase the
likelihood that a patient will treat transplant-jeopardizing co-morbidities and reduce their overall
financial burden (Chisholm 2007). Reducing the patient’s financial burden can help him obtain
the transplant services he desperately needs. Chisholm (2007) also notes that there are a number
of ways to obtain assistance with medication costs, including: commercial prescription
insurance, Medicare, Medicaid, private foundations, and pharmaceutical company medication
assistance programs.
In addition to help with the cost of transplant related medications, Medicare, Medicaid, and
Veteran’s Tricare all pay toward the cost of solid organ transplant. For individuals eligible for
Medicare under the End Stage Renal Disease diagnosis, the total cost of transplantation is
covered. In addition, though Medicaid programs vary by state, there is Medicaid insurance
available to non-elderly and elderly individuals who are indigent and need an organ transplant
(Center for Medicare and Medicaid Services 2009).
By overcoming these financial barriers to transplant, patients are able to qualify for transplant
center lists and receive organ transplants. This eliminates the inequality seen in transplantation,
and gives every patient a fair chance of receiving an organ. Additional support from the
transplant center through case management workers, social workers, and other coordinators helps
patients obtain necessary insurance in a timely fashion. With the possibility of insurance
enrollment denial, it is important that patients facing terminal illness without organ
transplantation seek out sources of funding for both the transplant and their medication before it
is too late in their disease process.
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Medical Tourism
Transplant medical tourism is an ethically controversial way for patients to obtain cheaper
organ transplants, often more quickly than in their developed home countries with modern
healthcare systems. For patients who are poor or lack adequate health insurance, seeking
overseas transplants not covered by Medicare or Medicaid might offer a cheaper alternative
when the other option is to die in the United States (Bramstedt and Xu 2007). Transplants
performed in China and India are a fraction of the cost of American transplants, and private
insurance groups have encouraged transplant tourism to reduce the initial surgical cost of
transplantation (Bramstedt and Xu 2007). Organs used in transplant tourism are recovered from
living and deceased donors. Typically deceased donor organs are reserved for patients within the
country’s normal organ donation system (if one exists). In under-developed countries with little
regulation surrounding living and deceased organ transplant, there is the opportunity for living
donor monetary compensation (Bramstedt and Xu 2007). In China, it is not known where the
majority of deceased organs come from due to the lack of transparency in Chinese organ
donation programs (Bramstedt and Xu 2007).
Aside from an American patient traveling with an uncompensated, un-coerced, consented,
living donor, the origin of organs available for transplant tourists is ethically questionable at best.
Residents of chronically underprivileged countries may feel forced into consenting to donation
when they are unable to feed their families, or do not feel comfortable saying no to their
government officials (Bramstedt and Xu 2007). There are also sanitation risks at many hospitals
in countries with underdeveloped healthcare systems. Transplant tourists often face
complications after returning to the United States (Bramstedt and Xu 2007). Infections, rejection
secondary to poor donor/recipient matching services, incomplete medical records, and an
inability to pay for expensive American aftercare are all issues related to transplant tourism
(Bramstedt and Xu 2007). However, if an American transplant patient is unconcerned with the
ethical and medical risks associated with transplant tourism, or has a living donor willing to
travel with her who is also unconcerned with the medical risks, transplant tourism does result in
cheaper transplant surgeries and remains an option for some American patients (Bramstedt and
Xu 2007).

CONCLUSION: TRANSPLANTS WITHOUT BARRIERS
Obviously, with the shortage of transplantable organs some patients will inevitably die on or
off transplant waiting lists; however, without financial barriers, it won’t be because of their
inability to pay. Transplantation programs without financial barriers give hope to terminally ill
patients and their families. Despite the lack of financial barriers to transplant as seen in countries
like Spain, Italy, the United Kingdom, and Japan, other barriers to donation exist, resulting in
overall lower numbers of transplants in these countries. Reducing the financial barriers to
transplant in the United States is a step in the right direction for medical ethics and patient
equality. The reduction of financial barriers combined with the culture of donation in the United
States and Spain could result in a donation and transplantation system that truly seeks to save
lives, lacking profit and market driven motives. As we take steps to decrease financial barriers to
organ transplant, we may see an increase in the amount of transplantable organs as donors and
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their families give consent, knowing that the process is truly free of financial influence. Putting
the politics of healthcare finance ahead of the importance of saving lives does a disservice to
American transplant patients who otherwise have access to the best medical care in the world.
Until there is radical change in the funding methods for organ donation in the United States,
patients will continue to die because they are not considered eligible for a transplant based on
their financial status. The American healthcare system’s bond to the financial market will
prevent OPOs and transplant surgeons from saving lives more valuable than the almighty dollar.
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